CCL2 and neoplasm: CC chemokine ligand‐2 (CCL2) has been found to not only elicit the insensitivity of tumor cells to chemotherapy and hormone therapy but also induce the resistance of tumor cells toward immunotherapy and targeted drugs such as sorafenib.32